DexCom Company Profile (NASDAQ:DXCM)

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) posted its earnings results on Tuesday, August, 1st. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The firm's revenue for the quarter was up 24.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.24) earnings per share. View DexCom's Earnings History.

When will DexCom make its next earnings announcement?

Where is DexCom's stock going? Where will DexCom's stock price be in 2017?

17 brokerages have issued 12-month price targets for DexCom's stock. Their predictions range from $66.00 to $100.00. On average, they expect DexCom's stock price to reach $87.00 in the next year. View Analyst Ratings for DexCom.

What are analysts saying about DexCom stock?

Here are some recent quotes from research analysts about DexCom stock:

1. According to Zacks Investment Research, "DexCom reported narrower-than-expected loss in the second quarter. We believe the company’s margins will continue to be under pressure in the coming quarters, owing to high product development costs and rising expenditures on research & development. Specifically, the company is expected to have lower margins on transmitter sales (in spite of the cost reduction initiatives). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a major headwind. In the past one year, DexCom has underperformed the broader industry in terms of price. On the positive side, the glucose monitoring market represents significant commercial opportunity for DexCom. The company has also signed collaborative agreements with several companies, which should not only bring in cash, but also help expand its product portfolio." (8/14/2017)

2. Jefferies Group LLC analysts commented, "DXCM reported 4Q sales $3mn ahead of its pre-announcement. Guidance for 2017 remained +25-30% ($710-740mn); importantly, this considers competitive entries by MDT (670G) and ABT (Libre), but does not factor in any contribution from DXCM patients covered by Medicare. With this low bar set for 2017, the next-gen G6 and the Verily Type 2 system coming in 2018, DXCM remains well positioned to succeed in an evolving diabetes landscape. The stock remains a top idea." (3/1/2017)

MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.